MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

NCT00706238 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.

Conditions

Interventions

Sponsor

GlaxoSmithKline